NEW YORK (GenomeWeb News) – Mayo Clinic and Mayo Medical Laboratories will offer BioTheranostics' CancerType ID molecular cancer classification test under a deal announced today.
The test is being offered as part of Mayo's surgical pathology consultants to help manage patients with metastatic cancer, and will be made available to Mayo Clinic physicians and patients. Additionally, Mayo Medical Laboratories will offer the test to the more than 5,000 hospitals it serves globally, BioTheranostics said.
CancerType ID predicts tumor type in patients with metastatic cancer. The real time, RT-PCR based assay determines the tumor site of origin by using the differential expression of 92 genes. Among the tumor types the product classifies are melanoma, kidney, thyroid, ovary, brain, sarcoma, and others. During the summer, San Diego-based BioTheranostics announced Tufts Health Plan and Highmark Health Services started covering the test as an in-network benefit.
Financial details of today's agreement were not disclosed.